Partial Epigenetic Reprogramming Enters Trial Phase: FDA Biomarker Standards Now Decide the Real Endpoints
Epigenetic clocks and methylation readouts are moving from lab proxies toward clinical posture, but FDA biomarker qualification defines what will count.